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Abstract Despite advances in myocardial reperfusion therapies, acute myocardial ischaemia/reperfusion injury and conse-
quent ischaemic heart failure represent the number one cause of morbidity and mortality in industrialized societies.
Although different therapeutic interventions have been shown beneficial in preclinical settings, an effective cardio-
protective or regenerative therapy has yet to be successfully introduced in the clinical arena. Given the complex
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pathophysiology of the ischaemic heart, large scale, unbiased, global approaches capable of identifying multiple
branches of the signalling networks activated in the ischaemic/reperfused heart might be more successful in the
search for novel diagnostic or therapeutic targets. High-throughput techniques allow high-resolution, genome-wide
investigation of genetic variants, epigenetic modifications, and associated gene expression profiles. Platforms such as
proteomics and metabolomics (not described here in detail) also offer simultaneous readouts of hundreds of pro-
teins and metabolites. Isolated omics analyses usually provide Big Data requiring large data storage, advanced com-
putational resources and complex bioinformatics tools. The possibility of integrating different omics approaches
gives new hope to better understand the molecular circuitry activated by myocardial ischaemia, putting it in the
context of the human ‘diseasome’. Since modifications of cardiac gene expression have been consistently linked to
pathophysiology of the ischaemic heart, the integration of epigenomic and transcriptomic data seems a promising
approach to identify crucial disease networks. Thus, the scope of this Position Paper will be to highlight potentials
and limitations of these approaches, and to provide recommendations to optimize the search for novel diagnostic
or therapeutic targets for acute ischaemia/reperfusion injury and ischaemic heart failure in the post-genomic era.
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1. Introduction
Myocardial ischaemia and reperfusion and its consequence heart failure
are the leading causes of death and disability in industrialized societies.1
Despite intensive research in the last three decades, there is still no car-
dioprotective drug on the market that can alleviate myocardial ischaemia
and reperfusion injury thereby reducing infarct size.2–4 Likewise, cardiac
regeneration has the therapeutic potential to prevent the development
of post-ischaemic heart failure.5 The lack of successful translation of
promising therapeutic strategies to the clinical arena includes several fac-
tors such as the use of hypothesis-driven, biased target discovery6,7 and
neglecting the interfering effects of common cardiovascular risk factors
and their routine medications with cardioprotective pathways.4,8
Therefore, for successful development of cardioprotective therapies for
acute myocardial ischaemia/reperfusion injury and ischaemic heart fail-
ure, new ways to discover valid targets must be used.
Since the completion of the Human Genome Project (HGP)9 a tre-
mendous effort has been undertaken through Genetics, Genomics, and
Functional Genomics studies to determine how this information might
be linked to a healthy or unhealthy cardiac phenotype, particularly in
myocardial ischaemia/reperfusion and the failing ischaemic heart.6
Despite great expectations, so far the clinical translation of basic
discoveries in the areas of genetics has produced disappointing results
(previously addressed by a Scientific Statement from the American
Heart Association,10 and not discussed here). Several additional mecha-
nisms related to epigenomic, transcriptomic, proteomic, and metabolo-
mic regulation might be crucial to determine the pathological phenotype
of myocardial ischaemia/reperfusion injury and ischaemic heart failure
(for a glossary of terms, please see Table 1). The combination of omics
techniques (Figure 1)11,12 might be extremely powerful and effective to
improve our understanding of the molecular mechanisms of myocardial
ischaemia/reperfusion, facilitate the development of ‘tailored’ care, and
in turn ameliorate the outcome of these patients. For example, a com-
bined proteomics and metabolomics analysis of murine hearts revealed
a reduction in succinate after preconditioning.13 Succinate was subse-
quently implicated in reperfusion injury through mitochondrial ROS gen-
eration.14 In addition, mass spectrometry is the method of choice for
the analysis of post-translational modifications involved in epigenomic
regulation, including histone modifications and the identification of
histone-associated proteins.15,16 Although neither proteomics nor
metabolomics can currently analyse the entire proteome or metabo-
lome of mammalian tissues, with the rapid advances in mass spectrome-
try instrumentation the coverage is becoming increasingly more
comprehensive.17–19
..............................................................................................................................................................................................................................
Table 1 Glossary of terms
Term Definition
Genetics Study of specific, individual genes, and their role in inheritance.
Genomics Study of genes, their functions, and biological effects.
Functional genomics Study of changes in gene products (transcripts, proteins, metabolites) and how these changes mediate normal and abnormal biological
function.
Comparative genomics The study to compare the genes in one organism with those of another.
Epigenetics The study of processes that lead to heritable changes in gene expression without changes in the DNA sequence.
Epigenomics Study of epigenetic modifications across the genome.
Epitranscriptomics Study of post-transcriptional RNA modifications not involving a change in the ribonucleotide sequence.
Gene expression The study of mechanisms translating information encoded by a gene into RNA structures or proteins.
Transcriptomics The study of the complete set of RNA transcripts that are produced by the genome under specific conditions.
Omics Suffix added to the names of many fields to denote studies undertaken on a large or genome-wide scale.
Proteomics The study of the complete set of translated proteins within a biological sample under particular circumstances.
Metabolomics Quantitative study of all intermediary metabolites in a given biological state.
Phenome The whole set of phenotypic entities in an organisms.
Diseasome All molecular or phenotype-based relationships between diseases observed in an organism.
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Many of the stress signalling pathways activated by myocardial ischae-
mia and reperfusion culminate in the nucleus, leading to alterations in
cardiac gene expression.20–22 A wide range of molecular players are
involved in the regulation of gene expression at multiple levels, including
transcriptional regulatory proteins binding specific DNA motifs in the
control regions of the genes, and epigenetic modifications, inducing
changes of gene expression without alterations in the gene sequence.
A variety and continuously increasing number of epigenetic mechanisms
modulating gene expression has been described (reviewed in23–27),
including ATP-dependent chromatin remodelling, ncRNA-based mecha-
nisms, covalent histone modifications, and DNA methylation. Moreover,
myocardial ischaemia/reperfusion injury and heart failure develop due to
a combination of the individual genetic make-up and interaction with car-
diovascular risk factors and co-morbidities accumulating during ageing,
that also affect cardiac gene expression profile and phenotype.6,8
How variations in global cardiac gene expression profile can directly
contribute to disease progression, the elucidation of the molecular sig-
nalling pathways underlying gene expression and the ensuing phenotype
is extremely complex. Microarray or sequencing-based techniques now
allow high-resolution, genome-wide investigation of both epigenomic
and transcriptomic landscapes, and the integration of results from these
approaches, with subsequent robust bioinformatics platforms to analyse
such ‘Big Data’ are emerging as promising strategies to identify key regu-
latory networks and signalling hubs in response to cardiac injury
(reviewed in6,12,24,26,28). However, the simple description of gene
expression modifications is not sufficient to demonstrate the mechanistic
role of all the modulated genes in myocardial ischaemia/reperfusion
pathophysiology. Better understanding how gene expression profile
affects cardiac phenotype, global cardiac protein expression including
post-translational modifications (i.e. proteomics) as well as their effect
on global cell metabolism (i.e. metabolomics) should be studied as well.
Along with these bright prospects, such innovations also represent a
new and great challenge. Thus, the aim of this Position Paper is to discuss
promises and pitfalls of high-throughput epigenomic and transcriptomic
(proteomics and metabolomics are not described here in detail) profiling
in myocardial ischaemia/reperfusion and ischaemic heart failure (proteo-
mics and metabolomics are not described here in detail), and to provide
recommendations to optimize the potentialities of these tools and iden-
tify novel diagnostic and therapeutic targets in the ‘post-genomic’ era.
2. Epigenomics and transcriptomics
in the ischaemic heart
2.1 Epigenomics
Although a large number of studies have investigated the role of epige-
netic mechanisms in cardiac development, postnatal maturation and
adverse cardiac remodelling in response to pressure overload,29–31 only
few studies have specifically investigated genome-wide epigenetic modifi-
cations in cardiomyocytes induced by myocardial ischaemia or in ischae-
mic heart failure. It has been recently demonstrated, using a combination
of chromatin immunoprecipitation followed by sequencing (ChIPSeq)
and microarray transcriptome profiling, that ischaemic preconditioning
promotes epigenetic repression of the Mtor gene and induction
of autophagy by enhancing dimethylation on lysine 9 on histone H3.32
In cardiac samples from end-stage heart failure patients, differences in
DNA methylation and distinct patterns of histone H3 methylation (lysine
26) could also be identified.33,34 Methylation differences in several genes
related to heart disease or with unknown function were also identified in
samples from patients with idiopathic dilated cardiomyopathy.35 In addi-
tion, satellite repeat elements were also found significantly hypomethy-
lated in end-stage cardiomyopathic hearts compared to healthy normal
controls.36 These findings collectively suggest an important role of epige-
netic modifications in ischaemic heart failure. However, it is still not clear
whether and when epigenomic modifications might be involved in the
development and progression of cardiac dysfunction promoting heart
failure, and whether their modulation might ameliorate the phenotype.
Work over the past decade has revealed important roles for reversi-
ble protein acetylation in cardiac development and disease.22,27 As small
molecule inhibitors of histone deacetylases are available and approved
for clinical use, there is much interest in repurposing these compounds
for cardiovascular indications in hopes of translating this biology into the
clinical domain.37,38 Although such compounds are already used in clini-
cal trials or daily practice in cancer patients, their potential cardiac effects
have been poorly described.39 Future studies will be needed to address
their effects in the ischaemic heart.
2.2 Transcriptomics
Transcriptomics studies in animal models of myocardial ischaemia/reperfu-
sion and ischaemic heart failure have clearly demonstrated the importance
of altered expression of genes involved in cardiac metabolism, cell growth
and survival, inflammation, cytoskeleton structure, and extracellular matrix
remodelling (recently reviewed in40). However, only a few studies per-
formed global gene expression profiling in ischaemic heart failure. Some
studies identified gene expression profiles differentiating between ischae-
mic and non-ischaemic cardiomyopathy41,42 and others compared tran-
scriptomics of failing and non-failing human tissue samples.43 However,
Kuner et al.44 revealed poor separation of human cardiomyopathies of
ischaemic and non-ischaemic aetiologies by gene expression profile.
ncRNA expression profile revealed a dynamic regulation of myocardial
ncRNAs in failing human heart and remodelling with mechanical circulatory
support.45 Although there is an increasing interest in protecting the
Figure 1 Schematic representation of a full omics approach.
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ischaemic heart by ischaemic conditioning and related cardioprotective
mechanisms,3 only a small fraction of conditioning studies assessed global
gene expression profile of the heart in response to ischaemic conditioning
and most of these studies are rather descriptive. The first studies in the lit-
erature using the pioneer DNA-chips showed that cardioprotection by
ischaemic preconditioning affected gene expression profile of the heart in
rabbits and rats more than was previously thought.46,47 These results have
been confirmed by several papers showing that ischaemic conditioning trig-
gers a cardioprotective gene expression profile in the heart at the tran-
script level.6 Moreover, changes in the expression of the post-
transcriptional regulators of gene expression, i.e. ncRNAs, have recently
been shown by ischaemic conditioning in rat hearts.48 However, little is
known about whether remote ischaemic conditioning may also affect the
global gene expression profile of the heart. Nevertheless, the study of
Simkhovich et al.47 showed that regional ischaemia led to changes in the
gene expression profile in the remote non-ischaemic area of the heart. So
far one paper has confirmed that remote ischaemic preconditioning leads
to alteration of gene expression profile in the heart in mice.49 In line with
this assumption, extracellular vesicles, potential carriers of microRNAs
(miR), have been shown to mediate the cardioprotective effect of remote
ischaemic preconditioning in rat hearts.50
Identification of global gene expression profile of the heart due to ischae-
mic conditioning stimuli may help to identify key cardioprotective pathways
to be targeted, e.g. by gene therapy (see for a recent review5). As an exam-
ple, by systematic comparisons looking at the direction of miR expression
changes due to ischaemia/reperfusion with or without conditioning stimuli,
potential cardioprotective miR targets termed ‘protectomiRs’ such as miR-
125b*, miR-139-3p, miR-320, miR-532-3p, and miR-188 have been identi-
fied.48 Similarly to myocardial ischaemia/reperfusion, changes in the global
cardiac gene expression profile including miRNAs has been shown during
the development of heart failure in different preclinical animal models51–53
as well as in human endomyocardial biopsies of heart failure patients.54,55
Moreover, transcriptomic studies have identified some miRNA clusters
(miR15, miR17/92, miR 302/367) and individual miRs (including miR-99/
Let-7c, miR-100/Let-7a, miR-199a, and miR-590), that control cardiomyo-
cyte proliferation and may exert potent cardiac regeneration of the adult
myocardium56–58 (reviewed in reference59).
2.3 Influence of risk factors, comorbidities,
and their pharmacological treatment
Several risk factors, ageing, comorbidities, and their drug treatments have
been shown to modulate gene expression profile of the normal and dis-
eased heart thereby modulating cellular signalling by either direct modifi-
cation of transcription factors, post-transcriptional, and/or post-
translational modifications or epigenetic mechanisms.6–8,60–65 Most of the
studies determined specific epigenetic patterns or transcriptomics in the
whole heart tissue or in circulating blood cells,6–8,57–62 but little is known
on the global gene expression or epigenetic regulation in the different cell
types of cardiac tissues. One study examined the gene expression profile
of patients with new-onset heart failure due to idiopathic dilated cardio-
myopathy, and revealed important sex-specific differences, i.e. 35 overex-
pressed and 16 down-regulated transcripts in men vs. women.66
Long-term effects of hyperlipidemia and obesity on cardiac gene
expression have been studied in some experimental models. Expression
of numerous genes was altered in rat hearts on cholesterol-enriched
chow for 2 months,67 in high-fat chow fed mice68, and in dogs after
9 weeks of high fat diet.69 In dogs fed a high-fat chow for 9–24 weeks,
a time-dependent decrease in expression of several genes implicated in
obesity-related cardiac pathologies, such as hypertrophy and fibrosis was
found.69 Expression of several miRs is altered in the ventricles of rats fed
a cholesterol-enriched chow.70 In this study, one of the most robust
down-regulation was found with respect to miR-25, which might be
responsible for the increased oxidative- and nitrosative stress observed
in the heart in this model.70 However, a more complex bioinformatic
analysis of the miRNA omics data is missing from this study.
Unfortunately no relevant human data are available on the effect of car-
diovascular risk factors on the global gene expression pattern of the nor-
mal or ischaemic heart. Although a study showed that the gene
expression pattern of the human atrium is significantly altered in obe-
sity,71 so far data are unavailable from ventricular samples that would be
relevant for myocardial ischaemia/reperfusion injury or ischaemic heart
failure. For more details on cardiac transcriptomic changes in response
to risk factors, see recent reviews.6,8
Data mining analysis has suggested an important role for epigenetic
factors in the pathogenesis of type 2 diabetes.72 However, most epige-
netic studies addressing the mechanisms and effects of diabetes were
performed in blood cells, endothelial cells, smooth muscle cells, or pan-
creatic cells,73–75 while limited information is currently available in car-
diac myocytes. Significant divergence in myocardial gene expression
profile has been observed in the hearts of the diabetic Otsuka Long-
Evans Tokushima fatty rats when compared to the non-diabetic con-
trols76 and in Zucker diabetic fatty compared to control lean rats.77 In
type 1 diabetic rats, transcriptomic changes were responsible for altered
myocardial metabolic substrate utilization that may account for the exag-
gerated progression of post-infarction remodelling.78 Moreover, altera-
tions in miR expression profile in the heart of type 1 diabetic rats
coupled with bioinformatic target prediction suggested that the affected
miRs make a significant contribution to the myocardial transcriptomic
profile involved in hypertrophy and fibrosis.79,80
Currently used drugs to treat comorbidities of myocardial ischaemia
may modify the response of the heart to ischaemia/reperfusion injury via
several mechanisms including changes in cardiac gene expression
pattern.8 For example, excessive use of nitrate inducing nitrate tolerance
also modifies gene expression profile of the heart and leads to disruption
of cardioprotective pathways.81 Statins are potent cholesterol-lowering
drugs that are widely used in clinical practice for primary and secondary
prevention of coronary heart disease. Although some rodent studies
showed alterations in cardiac gene expression profile due to treatment
by different statins82,83 and despite the abundance of clinical studies
investigating the effects of statins, little is known regarding the effects of
this class of drugs or other widely used anti-hyperlipidemic drugs on car-
diac gene expression.
2.4 Role of mitochondria?
Although most DNA is nuclear, mitochondria also contain a small
amount of mitochondrial DNA (mtDNA). Mitochondria have been
shown to ‘interfere’ with epigenetic modifications of nuclear DNA by
several mechanisms.81,84 Moreover, mtDNA mutations have been
recently associated with coronary heart disease.82,85 The possibility that
mtDNA might directly undergo epigenetic modifications (in particular
DNA methylation since mammalian mtDNA lacks histones) has been
questioned and extensively investigated for several years.86 Although
mtDNA contains a lower number of CpG dinucleotides compared to
nuclear DNA and lacks CpG islands, it has been recently proposed that
epigenetic modifications of cytosines in mtDNA might be much more
frequent than previously believed.87 Mitochondria-specific oligonucleo-
tide microarrays have been developed to analyse the expression levels
728 C. Perrino et al.
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of genes important for mitochondrial function encoded by nuclear or
mtDNA in different in vitro and in vivo mouse models and in humans,
mostly utilized in hypoxia, toxicogenomics, and aging.87,88 Future studies
will be needed to determine whether and how changes in cardiac
mtDNA methylation or mitochondrial transcriptomics patterns are
associated with myocardial ischaemia and its comorbidities.
3. Prospects and pitfalls of
epigenomic and transcriptomic
profiling in the ischaemic heart
3.1 Prospects of unbiased omics
approaches
Epigenomic and transcriptomic profiling provide quantitative informa-
tion about epigenetic changes, gene expression and splicing variants,
and allow to study variations in the heart throughout disease progres-
sion and in response to environmental changes or treatments. As
global approaches, they provide large quantities of data that can be
used for unbiased assessment of pathophysiological processes with-
out a priori assumption (Figure 2). Newer techniques such as ribo-
some sequencing (Ribo-seq), which report only those transcripts that
are being actively translated, might allow a more nuanced interroga-
tion of the transcriptional landscape.89 Correlation and causality asso-
ciations obtained from bioinformatic analyses of these data might
represent a great opportunity for researchers to gain important novel
insights into the mechanisms underlying myocardial ischaemia and
reperfusion. In contrast to other approaches targeting a putative, sin-
gle molecular target, this strategy might be more helpful to identify
multiple key targets determining cardiac dysfunction in response to
ischaemia and reperfusion. Once identified crucial networks in pre-
clinical studies and/or in patient’s samples, more focused analyses of
specific pathways or targets might offer the potential for rapid diag-
nostics and prognostics, drug safety testing and patient selection, and
stratification for clinical trials. In addition to single-centre experiences,
international consortia have been developed to share datasets,
resources and protocols, providing a large amount of freely available
information that is likely to exponentially increase in the near future
(see for example reference90).
Figure 2 Schematic representation of unbiased experimental omics approach (A) or hypothesis-driven traditional approach (B).
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Thus, authors of this Position Paper believe that compared to
hypothesis-driven investigations, a non-hypothesis-driven research
approach through omics methodologies have a strong potential to speed
up the discovery process and give broader insight into signalling hubs
activated by myocardial ischaemia/reperfusion injury together with its
co-morbidities and their routine medications.
3.2 Technical and experimental pitfalls
Despite these promising aspects, there are multiple pitfalls when dealing
with epigenomic and transcriptomic analysis in the ischaemic heart.
Major technical problems are the heterogeneity within biological speci-
mens, the quality of RNA and DNA (integrity, DNA contamination), and
the insufficient availability of clinical samples from patients with myocar-
dial ischaemia and reperfusion of ischaemic heart failure. Indeed, access
to human cardiac tissues is often limited and, when possible, it usually
involves samples from end-stage heart failure explanted hearts. These
hearts have usually undergone multiple treatments and present relevant
comorbidities that might directly or indirectly affect gene expression and
epigenetic patterns. Cardiac tissue samples often contaminated by blood
may also alter their omics readouts. Moreover, fresh healthy hearts are
not easily available making the comparison with appropriate control
groups often extremely challenging.
Given the relative inaccessibility of cardiac tissue, alternative sources
have been considered, including human cell-based samples such as whole
blood or white blood cells, or cell-free DNA samples from the plasma.
The rationale supporting the use of these samples is that cardiac cells
may release epigenetically modified DNA or that blood cells may have
undergone changes similar to cardiomyocytes. Although future investiga-
tions focused on this topic might be extremely interesting and valuable,
at the present time the mechanisms underlying this potential ‘mirroring’
are not clearly demonstrated, and therefore studies focusing on cardiac
tissue and cells are recommended.
Preclinical studies using animal models have been extremely helpful and
valuable as they allow the investigation of the progress of mechanisms of
adverse remodelling towards end-stage heart failure, and comparisons of
genomic expression across species often identifies patterns of evolutionary
conserved transcriptional profiles among mammalian species. However,
species-specific expression patterns have also been described,91 and even
in the presence of high-degree homology between species, there might be
small but significant differences in the activated intracellular pathways.92
Moreover, the role of genetic background even in the same species is still
not clearly established yet.93 A vast array of heart failure-related genetically
modified mouse models has been produced since the techniques became
available.94 Cardiac-specific inducible and conditional gene targeting in
mice has greatly enlarged our understanding of the function of individual
genes or even gene variants.94 However, the potential importance of adap-
tations in the heart to the altered expression of a single gene may modify
the global gene expression pattern of the heart.
Whatever the experimental model used, since cell-specific gene expres-
sion and epigenetic profiles have been consistently reported, it would be
ideal to focus and profile specific cell types, rather than the whole tissue, in
which the underlying changes might be small and diluted by the presence
of non-affected cells. In this regard, it would be crucial to define the target
cell type, and describe the methods used to isolate, characterize, culture
and eventually treat the cells. Studies have been performed with purified
populations of cardiomyocytes obtained using different techniques25,29,30
or isolating cardiomyocyte nuclei from the heart by magnetic or
fluorescent-assisted sorting.95 The isolation procedure of a specific cell-
type and cell culturing might also cause changes in RNA expression and
epigenetic profiles, thus affecting the analysis.96 Single-cell techniques to
perform transcriptomic analysis are already available and have been used
to study gene expression during cardiogenesis in vitro,96,97 even if they are
not yet in widespread use. Such technologies may also provide insights
into the cellular heterogeneity of tissues as recently elegantly shown for
cardiac fibroblasts.98 Single cell approaches also might be especially useful
when myocardial ischaemia is treated by cell-based therapies, often after
genetic manipulation of the transplanted cells (see for review reference5).
From a temporal standpoint, most studies so far have analysed static
expression data, such as snapshots in different disease states. This
approach might fail to detect disease-causing events that are transient.
By using this kind of analysis, it is difficult to determine the changes
directly or indirectly initiated by myocardial ischaemia. In addition, static
expression data limit the use of reverse engineering approaches to infer
a network of gene interactions. In contrast, a dynamic approach describ-
ing changes in expression profiles at different time points during the
course of a disease would allow network-based analysis and provide
novel biological hypotheses.99 Yet, only very few temporal data sets
exist, and the majority of these datasets are limited to blood samples or
specimens of patients of different age and conditions. Longitudinal stud-
ies describing heart disease in individuals appear rather impossible, how-
ever, longitudinal studies using animal models appear promising to infer a
network of gene interactions, elucidate underlying mechanisms of heart
diseases, and to develop novel therapies.
The number and diversity of transcriptomic and epigenomic profiling
techniques is so wide that it can be challenging to select the best one.
Although a complete review of all possible methodologies is beyond the
scope of this Position Paper, major advantages and disadvantages of the
most commonly used techniques for transcriptomics and epigenomic
profiling are reported in Table 2. Different results may be obtained by
using different technologies, and even with the same technology, variabil-
ity might start in the wet lab, using different myocardial portions, sample
storage conditions, processing methods, and timing. For all these rea-
sons, for high-throughput sequencing could be considered running in
duplicates of biological samples. In addition, when RNA is prepared and
subsets are enriched or depleted (e.g. poly-A or ribo-minus selection),
preparation of libraries, sequencing methods (e.g. strand specific
sequencing), as well as the depth of the sequencing and bioinformatics
analysis can yield strikingly different results depending on, e.g. the map-
ping to the reference genome and annotations.100 Such technical details
may become major obstacles when comparing independent studies,
which not only use different experimental conditions and platforms, but
also varying bioinformatics approaches making potential meta-analyses
difficult or useless. Re-analysing raw data may help to overcome at least
the variability introduced by the bioinformatics analysis, but may not
avoid heterogeneity introduced by the wet lab. Thus, in order to reduce
variability, robust and streamlined methods, gold-standard instrumenta-
tions, and only widely accepted protocols should be employed to obtain
optimal starting samples. Taken together, although generation of omics
data could be better harmonized by more standard techniques, novel
bioinformatics models may still allow analysis of disease-specific molecu-
lar networks from rather heterogeneous data sets as well.
Authors of this Position Paper believe that cardiac tissue samples and
isolation of specific cell types should always be preferentially used to
derive information on epigenomic and transcriptomic targets in the
ischaemic heart whenever possible. Although we recognize the relative
inaccessibility of human cardiac tissues in the daily clinical practice, cardiac
tissue samples should be preferentially used to derive information on epi-
genomic and transcriptomic targets related to myocardial ischaemia
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Table 2 Advantages and disadvantages of major genome-wide transcriptomic and epigenomic profiling techniques
Method Advantages Disadvantages
TRANSCRIPTOMIC PROFILING
qRT–PCR microarrays • Widely available
• Low costs for selection of genes
• High precision and sensitivity
• Increasingly multiplexed
• High costs for genome-wide analysis
• Normalization sensitive to method/choice of reference
genes
• Not suitable for discovery of novel gene transcripts
cDNA microarrays • Relatively low costs
• Established method
• Useful for large transcriptomes
• Easy
• Fast
• Prior probe selection
• Probe redundancy and annotation
• Sensitivity due to hybridization (background hybridization,
probe saturation)
• Complex computational analysis
• Difficult absolute quantification
• Not suitable for discovery of novel gene transcripts
• Required validation by QRT–PCR
SAGE • Lack of hybridization problems
• Suitable for discovery of novel gene transcripts
• No need to know sequence in advance
• Tag specificity (multiple transcripts might have the same tag)
• High costs and long times
• Required recognition site for restriction enzyme
• Dependency on restriction enzyme function
• Tag annotation
MPSS • No need to know sequence in advance
• Suitable for discovery of novel gene transcripts
• Digital data easy to store in databases and compare
• Larger library size and longer signatures compared to SAGE
• Detection of lower expression levels transcripts
• Tag specificity (multiple transcripts might have the same tag)
• High costs and long times
• Required recognition site for restriction enzyme
• Restriction enzyme function
• Tag annotation
• Still relatively new
NanoString • Versatile
• Useful for clinical applications
• Library and processing not needed
• Sequence selection
• Not suitable for discovery of novel gene transcripts
• Hybridization problems
• Medium-throughput
RNA-Seq • Analysis of any RNA type
• No need to know sequence in advance
• Reliable on low abundance transcripts
• Suitable for discovery of novel gene transcripts
• Identification of genetic variants and isoforms
• Broader sensitivity to highly expressed transcripts
• Not yet suitable for low amount of samples
• Complex computational analysis
• RNA fragmentation
• Storage of a large amount of data
EPIGENOMIC PROFILING
DNA methylation
CHARM • Low costs
• Irrespective of proximity to genes or CpG islands
• Moderate resolution
• Limited to regions next to restriction enzyme sites
• Does not detect 5hmC
MBDCapSeq • Relatively low costs
• MBD proteins can discriminate between 5mC and 5hmC
• Relatively low resolution
• No absolute quantification of methylation levels
• Dependent on MBD binding sensitivity and specificity
• Does not identify single 5mC sites
• Sensitive to CpG density and copy numbers
MeDIPSeq • Relatively low costs
• Detection in regions with higher and lower CpG density
• Antibodies can also identify 5hmC (hMeDIP-Seq)
• Feasible with small amounts of DNA
• No absolute quantification of methylation levels
• Does not identify single 5mC sites
• Dependent on antibody sensitivity and specificity
• Resolution of 100–300 bp
• Sensitive to CpG density and copy numbers
Continued
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..whenever possible. Alternative and more accessible sources of human
biological material (whole blood, serum, white cells, plasma, urine, etc.)
can be used only if the mechanisms underlying the potential mirroring of
the heart in these samples are clearly demonstrated and validated.
3.3 Target identification: importance of
bioinformatics
Target discovery is the crucial initial step in biomarker and drug develop-
ment. Undoubtedly, a critical aspect in the search of novel targets in the
post-genomic era is probably no longer data generation, but rather data
analysis and interpretation. The search, identification, validation, and
interpretation of novel disease-associated targets will require innova-
tions in high-throughput technologies, biostatistics and bioinformatics,
and will necessitate interdisciplinary expertise and teamwork of clini-
cians, biologists, biochemists, and bioinformaticians. In this context, final
data interpretation usually develops in a multidisciplinary, shared envi-
ronment. Accordingly, bioinformatics has undoubtedly gained wider
prominence over the last decade in myocardial ischaemia/reperfusion
and other research areas. Bioinformatics areas of interest include the
development of new algorithms and statistics to assess relationships
among members of large data sets, the ability to analyse and interpret dif-
ferent types of sequences, domains, and structures, and the capacity to
develop or implement tools enabling efficient access and management of
different types of information. A large number of methods, including pat-
tern recognition algorithms, network analysis, and other artificial
intelligence-based algorithms have been applied to bioinformatics
research and will not be discussed here in detail.12,101–103 In general, all
approaches are characterized by specific advantages or limitations for
target identification and, in order to apply a ‘tailored’ bioinformatics
approach to the research plan, it is usually necessary to accurately pre-
determine and focus on the elements to be investigated, on the interac-
tions between the different elements, on the mathematical models to
describe these interactions and on statistics to be used to analyse the
data.99 Thus, combining biological concepts with computer tools or stat-
istical methods it is possible to discover, select and prioritize targets.
Importantly, ‘targets’ should be broadly considered molecular entities
(such as genes, proteins, RNA, and their modifications) as well as biologi-
cal phenomena (such as molecular functions and signalling pathways).
The complex features induced by myocardial ischaemia are difficult to
‘capture’ using single omic data modality, addressing only one mechanism
of disease. There is now significant interest in the use of multiple high-
throughput omic data for the identification of novel molecular subtypes of
a disease. Integration of expression data with epigenetic datasets is a prom-
ising strategy to improve accuracy of the inferred networks, enable the
..............................................................................................................................................................................................................................
Table 2 Continued
Method Advantages Disadvantages
Methylation microarrays • Relatively low costs
• High sensitivity
• Medium coverage (not every CpG site)
• To date only for human samples
WGBS • Methylation state of almost every CpG site
• Can distinguish between 5mC and 5hmC if bisulfite sequenc-
ing is performed after chemical oxydation of 5hmC to 5fU
(oxBS)
• High costs
• DNA degradation after bisulfite treatment
• Does not discriminate between 5mC and 5hmC
RRBS • Relatively low costs
• High sensitivity and coverage
• DNA degradation after bisulfite treatment
• Does not discriminate between 5mC and 5hmC
• Limited to regions next to restriction enzyme sites
• Lower coverage at distant and intergenic regulatory sites
TabSeq • Can distinguish between 5mC and 5hmC
• High sensitivity and coverage
• High costs
• DNA degradation after bisulfite treatment
• High sequencing depth required to detect 5hmC
• Conversion dependent on efficiency of Tet enzymes
Histone modifications
ChIPchip • Relatively low costs • Labor and skill intensive
• Can be limited by operator experience
• Array-specific resolution
• Requires higher amounts of ChIP DNA
• Lower detection limit
• High signal saturation
ChIPSeq • Single nucleotide resolution
• Lower amounts of ChIP DNA
• Labor and skill intensive
• Can be limited by operator experience
• High costs
qRT–PCR, quantitative real-time PCR; SAGE, serial analysis of gene expression; MPSS, massively parallel signature sequencing; RNASeq, RNA-sequencing; CHARM, comprehensive
high-throughput arrays for relative methylation; MBDCapSeq, methyl-CpG-binding domain (MBD) capture by affinity purification followed by sequencing; MeDIPSeq, followed by
sequencing; WGBS, whole genome bisulfite sequencing; RRBS, reduced representation bisulfite sequencing; TabSeq, tet-assisted bisulfite sequencing; ChIPchip, chromatin immuno
precipitation followed by microarrays; ChIPSeq, chromatin immuno precipitation followed by sequencing.
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..discovery of new insights and create a global perspective from which novel
diagnostic, prognostic or therapeutic targets in the ischaemic heart could
be discerned. Despite the abundance of genome-wide transcriptomic and
epigenomic datasets, there is a surprising shortage of statistical tools aimed
at their specific integrative analysis. Such integrative tools might be crucial
for the discovery of novel subnetworks (disease module) and/or relevant
molecular pathways. Combination of these methods usually entails specific
difficulties, and therefore establishing the concepts and fundaments of data
integration is clearly needed. Traditional database techniques are not
focused on the problems that arise in the search and finding of data in
large, not pre-organized repositories, for linking what is found to other
data, or for reusing and repurposing the data without significant effort.
Moreover, different omics data have different distributions and variation
patterns that configure data heterogeneity. In addition to the specific varia-
tion patterns in each layer of information, inter-layer regulatory co-
variations can be identified, increasing complexity. While multiple pro-
grams and web services are available for the analysis of single omics data,
the majority of these tools has a command-line interface, performs only
one specific task and typically requires file conversions. To better explore
and integrate multiple omics data modalities (for example epigenetic, tran-
scriptional, proteomic, and metabolomic modifications), novel and more
sophisticated bioinformatics methods, that can seamlessly account for the
networked nature of the subcellular environment, and that are simple to
use by the general research community would be needed.
Authors of this Position Paper believe that in order to fully realize the
scientific value of the vast amount of omics data, it is essential to fill the
gap between data generation and investigators’ ability to retrieve and
interpret the data. Most network and clustering methods proposed to
identify molecular targets were developed for single omic data types and
may not be appropriate when more than one omic data type is collected
in the same study subjects. To better explore and integrate multiple
omics data modalities, novel and sophisticated bioinformatics methods
would be needed, allowing automated, systematic, and unbiased identifi-
cation of targets. This approach will need more financing and more col-
laboration between cardiovascular and bioinformatic research groups,
ideally hiring biomedical scientists with strong bioinformatic expertise,
a species hardly found due to gaps in biomedical education.
3.4 Data availability, storage, and sharing
Collaborative research is usually the rule in this field, and it requires
implementation of an integrative framework with standardization of data
formats and possible access to the data from multiple web-based user
positions. Distinct data warehousing approaches have been used, and
which is more useful is yet to be determined. Shared warehousing possi-
bilities and software components might be extremely helpful for success-
ful collaborative work. Moreover, since several heterogeneous
databases are currently available and more are under steady develop-
ment, a standardized interface might represent an important target of
research for developers. In general, more advanced and powerful com-
puting will be needed in the future for large-scale omics analysis in terms
of hardware and development of novel software. Additional issues
regarding security and appropriate control of access to data, privacy pro-
tection, protection by backup, ethical issues, real-time availability and
eventually data mobility will also likely be a matter of research and dis-
cussion in this field. These next-generation post-genomic challenges will
need to be addressed in the future by computer developers, researchers,
and the general population of patients who might benefit from the
potential applications of these studies.
Various datasets derived from different detection systems are in need of
harmonization as most profiling studies are performed using dissimilar plat-
forms, requiring re-analysis of existing raw datasets, and after harmonization
of datasets. Since availability of data is crucial for validation of the bioinfor-
matics approach, authors of this Position Paper recommend that publishers
and researchers commit to make freely available all relevant information,
raw data sets, and their analysis. Details of protocols are essential allowing
investigators to compare or pool data sets. As soon as technologies
become state-of-the-art, the development of standard operating proce-
dures (SOPs) might be helpful to provide guides for the research commun-
ity. Moreover, acquired data should be stored and managed in open-
source, web-based platforms for data-intensive biomedical research.
3.5 Target validation
After in silico identification of key gene/RNA/protein targets by different
bioinformatic tools analysing epigenomic and transcriptomic data, exper-
imental validation of these predicted molecular targets at the protein
level is essential. Using in vitro cellular systems (genome editing, transfec-
tions, etc.) for target validation has become a relatively easy approach.70
However, target validation in vivo in the target disease models preferably
in the presence of relevant co-morbidities, obviously cannot be
spared.6,8 An obvious pitfall of such in vivo validation is that the
translational value of routinely used in vivo disease models of myocardial
ischaemia/reperfusion and heart failure is not sufficient (e.g. lack of
comorbidities and co-medications), and the cost of such target validation
is relatively high. Nevertheless, an increasing number of credible data on
cellular signalling in health and disease in multiplex preclinical disease
models and from human samples will lead to creation of an accurate dis-
ease module, a subnetwork of the full human interactome, integrating
knowledge from DNA, epigenome, transcriptome, proteome, and
metabolome.104 Since the network analysis approach of Big Data is
somewhat tolerant to input of data with heterogenous quality, this will
allow us to integrate data in the ischaemic heart in the context of the ‘dis-
easome’, allowing us to explore its relationship to common cardiac
comorbidities and other diseases.104
Authors of this Position Paper believe that predicted targets identified
by bioinformatics approaches from omics studies should be always vali-
dated in order to avoid generation of purely descriptive data and
Table 3 Major recommendations
• Unbiased bioinformatic analysis of full epigenomic and transcriptomic profiles of the ischaemic heart (preferably including proteomic and metabolomic data)
may lead to identification of novel molecular targets;
• Cardiac tissue samples should be used for omics assays and cell-specific analysis should be attempted;
• User friendly bioinformatic tools should be developed for target prediction from large omics data;
• Omics data should be stored in open-access databases to enable their analysis by the global scientific community;
• Experimental validation of predicted targets should be performed in relevant models of the ischaemic heart.
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..putative predictions. This Working Group recommends that a heart-
specific targeted approach in relevant disease models should always be
used for validation whenever possible.
4. Conclusions and
recommendations
Omics technologies have the potential to revolutionize our understand-
ing of complex diseases at the molecular network level. In order to opti-
mize the search for novel diagnostic or therapeutic targets for the
ischaemic heart in the post-genomic era, this Working Group provides
the following recommendations (summarized in Table 3):
1. Compared to hypothesis-driven approaches based on a priori target
selection, global, unbiased assessment of epigenomic and transcriptomic
profiles (preferably together with proteomic and metabolomic profiles)
combined with bioinformatics and biostatistics evaluations have the poten-
tial to identify multiple novel molecular targets in the ischaemic heart;
2. Whenever possible, cardiac samples should be used as sources of
biological material and cell-specific analysis should be attempted.
3. To better explore and integrate multiple omics data modalities,
complex but simple to use bioinformatics tools should be developed,
allowing automated, systematic, and unbiased identification of targets.
4. Publishers and researchers should always commit to make freely
available all relevant data sets and their analyses. Acquired data should
be stored and managed in open-source, web-based platforms for data-
intensive biomedical research.
5. After the unbiased, non-hypothesis-driven target identification, exper-
imental validation should be performed in relevant experimental models of
myocardial ischaemia and reperfusion and ischaemic heart failure to avoid
generation of purely descriptive data with putative predictions.
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